Antitumor agent-69
Antitumor agent-69 (compound 12) is a potent inhibitor of protein-protein interaction between DOT1L and MLL-AF9/MLL-ENL, with Kis of 9 nM and 109 nM for AF9 and ENL, respectively. Antitumor agent-69 exhibits anticancer cellular activitiy.
For research use only. We do not sell to patients.
- CAS No.: 2417651-42-2
- Formula: C43H62N8O5
- Molecular Weight:771.00
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Histone Methyltransferase Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| K562 | IC50 |
59 μM
Compound: 12
|
Anticancer activity against human K562 cells assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method
Anticancer activity against human K562 cells assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method
|
[PMID: 35612819] |
| KOPN-8 | IC50 |
0.1 μM
Compound: 12
|
Anticancer activity against human KOPN-8 cells harbouring MLL-ENL assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method
Anticancer activity against human KOPN-8 cells harbouring MLL-ENL assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method
|
[PMID: 35612819] |
| MOLM-13 | IC50 |
0.07 μM
Compound: 12
|
Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method
Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method
|
[PMID: 35612819] |
| MOLM-13 | IC50 |
167 nM
Compound: 12
|
Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 7 days measured by CCK-8 kit method
Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 7 days measured by CCK-8 kit method
|
[PMID: 35612819] |
| MOLM-13 | IC50 |
382 nM
Compound: 12
|
Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 6 days measured by CCK-8 kit method
Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 6 days measured by CCK-8 kit method
|
[PMID: 35612819] |
| MOLM-13 | IC50 |
44 nM
Compound: 12
|
Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 9 days measured by CCK-8 kit method
Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 9 days measured by CCK-8 kit method
|
[PMID: 35612819] |
| MOLM-13 | IC50 |
703 nM
Compound: 12
|
Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 5 days measured by CCK-8 kit method
Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 5 days measured by CCK-8 kit method
|
[PMID: 35612819] |
| MOLM-13 | IC50 |
972 nM
Compound: 12
|
Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 4 days measured by CCK-8 kit method
Anticancer activity against human MOLM-13 cells harbouring MLL-AF9 assessed as inhibition of cell growth treated for 4 days measured by CCK-8 kit method
|
[PMID: 35612819] |
| MV4-11 | IC50 |
0.22 μM
Compound: 12
|
Anticancer activity against human MV4-11 cells assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method
Anticancer activity against human MV4-11 cells assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method
|
[PMID: 35612819] |
| RS4-11 | IC50 |
0.24 μM
Compound: 12
|
Anticancer activity against human RS4-11 cells assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method
Anticancer activity against human RS4-11 cells assessed as inhibition of cell growth treated for 8 days measured by CCK-8 kit method
|
[PMID: 35612819] |
Chemical Information
-
CAS No. 2417651-42-2
-
Molecular Weight 771.00
-
Formula C43H62N8O5
-
SMILES
O=C([C@H]1N(CCC1)C(CCC(C)C)=O)N[C@@H](C(C)C)C(N[C@@H](CNC)C(N[C@@H](CC2CCCC2)C(N[C@H](C3=NC4=CC=CC(C5=CC=CC=C5)=C4N3)C)=O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Pull-down
The pull-down assay is an in vitro technique used to detect physical interactions between two or more proteins and an invaluable tool for confirming a predicted protein-protein interaction or identifying novel interacting partners. This method typically involves the use of affinity purification with various wash and elution steps.
-
Immunoprecipitation
Immunoprecipitation (IP) is an experimental method that uses the principle of antibody specific binding to purify and enrich target proteins.
-
Protocol for Bimolecular Fluorescence Complementation (BiFC) Assay
Bimolecular fluorescence complementation detects protein-protein proximity in living or fixed cells by fusing two candidate interaction partners to nonfluorescent N- and C-terminal fragments of a fluorescent protein; when the partners interact or remain close enough, the fluorescent fragments complement, mature, and generate a fluorescent signal at the site of the protein complex. The BiFC readout is fluorescence intensity and subcellular localization of the reconstituted fluorophore, which reflects formation or stabilization of a protein complex rather than direct biochemical binding kinetics; BiFC is therefore useful for mapping where interactions occur in cancer cells, neurons, macrophages, organoid-derived cells, or drug-screening systems, but results should be validated by independent assays such as co-IP or Western blot. BiFC signal formation is delayed by fluorophore maturation and can stabilize otherwise transient complexes, so it is not a real-time reversible interaction assay
-
Co-Immunoprecipitation
Co-immunoprecipitation technology can verify protein interaction based on the specific immune reaction between antibodies and antigens.
-
Protocol for Yeast Two-Hybrid (Y2H) Assay
The yeast two-hybrid assay detects binary protein-protein interactions by separating a transcription factor into a DNA-binding domain fused to a "bait" protein and a transcriptional activation domain fused to a "prey" protein; if bait and prey interact in yeast, the transcription factor is reconstituted and activates reporter genes such as HIS3, ADE2, lacZ, MEL1, or other selectable/readable reporters. The readout is yeast growth on selective medium and/or reporter activity, which reflects proximity-dependent transcriptional activation in the yeast nucleus rather than direct biochemical binding in the original mammalian, tumor, neuronal, macrophage, or organoid context. Because yeast two-hybrid can generate false positives and false negatives, interaction claims should be validated using independent assays such as co-immunoprecipitation, Western blot, immunofluorescence colocalization, BiFC, pull-down, or mammalian two-hybrid assays.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)